The Change Of Plasma Soluble Low-density Lipoprotein Receptor-related Protein-1in Acute Coronary Syndrome

Background and Objective:Low-density lipoprotein receptor-related protein-1(LRP-l) is one of the mostversatile low-density lipoprotein receptor super family (LDLRs). The main functionsof LRP-l are ligands endocytosis and the regulation of cell signaling pathways. It isreported that LRP-l is shed by some inflammatory cytokines and functional solubleLRP1(sLRP1) has been detected in circulating human placenta. Additionally, the studyshowed that the plasma level of sLRP-1was elevated in the patients with inflammatorydisease such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).Acute coronary syndrome (ACS) is a clinical syndrome induced by coronaryatherosclerotic vulnerable plaque rupture and thrombosis and inflammatory responsealso take part in it. In this study, we observed the change of sLRP-1in the plasma ofpatients with ACS and analyzed the association of sLRP-1levels with the levels ofregulated upon activation normal T cell expressed and secreted (RANTES) and severityof coronary atherosclerosis.Methods:76patients were enrolled in this study, including60ACS patients and16patientswithout coronary atherosclerosis by coronary angiography (CAG) as control group.ACS patients contained20unstable angina (UA) patients and40acute myocardialinfarction (AMI) patients.Their age ranged from45to75, with an average age of61.60±11.48years. All of them had CAG and then Gensini score was calculated. All patientswere made a detailed record of the general condition and the results of the routineexamination, collected peripheral blood2mL at admitted to hospital immediately. ACSpatients were collected peripheral blood2mL again at1week of treatment (more than48hours after CAG). The levels of plasma sLRP-1and RANTES were measured by ELISA. Data was analyzed by SPSS18.0statistical software. sLRP-1(μg/mL) was rightskewed distribution, and it was used for statistical analysis after turned normaldistribution by taken lg. p<0.05was statistically significant.Results:1. The plasma levels of lg sLRP-1in AMI group at admitted to hospital immediately(0.54±0.24μg/mL) were higher than control group(0.27±0.18μg/mL)(P﹤0.05), andlittle higher than UA group(0.53±0.25μg/mL)(P＞0.05). It decresed in AMI group at1week of treatment (0.32±0.21μg/mL)(P﹤0.05). The plasma levels of lg sLRP-1in UAgroup at admitted to hospital immediately were higher than control group (P﹤0.05),and decreased at1week of treatment (0.38±0.19μg/mL)(P﹤0.05). The plasma levelsof RANTES in AMI group at admitted to hospital immediately (122.57±33.59pg/mL)were higher than control group(93.98±22.06pg/mL)(P﹤0.05), and higher than UAgroup(118.63±22.31pg/mL)(P＞0.05). It decresed in AMI group at1week oftreatment (101.84±27.85pg/mL)(P﹤0.05). The plasma levels of RANTES in UAgroup at admitted to hospital immediately were higher than control group (P﹤0.05),and decreased at1week of treatment (98.22±24.62pg/mL)(P﹤0.05).2. The plasma levels of sLRP-1in ACS patients showed a positive correlation toRANTES at admitted to hospital immediately (r=0.53, P﹤0.01) and the linearregression equation was y=0.71+0.004x(y: The plasma levels of sLRP-1, x: The plasmalevels of RANTES). The plasma levels of sLRP-1in ACS patients at admitted tohospital immediately showed a negative correlation to Gensini Score(r=-0.71，P＞0.05).Conclusion:1. The expression of sLRP-1and RANTES increases in patients with ACS and therewas a positive correlation between them. sLRP-1may be one of the indicators of plaqueinstability.2. The plasma levels of sLRP-1in ACS patients were no correlation with GensiniScore, so sLRP-1could not be the indicator of assessing for the severity of coronaryatherosclerosis.